NICE clarify ACS guidance

October 31, 2005 at 10:59 am | In Prescribing Extra - Other |

NICE have clarified their guidance in relation to the use of Clopidogrel (Plavix) in Acute Coronary Syndromes (ACS).

The original recommendation stated that the combination of aspirin and clopidogrel should be used for up to 12 months after the most recent event.

They have now clarified that the evidence of efficacy and cost-efficacy extends to 12 months, as determined by the clinical trials. Clinicians and funding bodies should not have discretion to change the period of treatment.

Action: Clinicians should be aware of this clarification. Clopidogrel should be prescribed for 12 months treatment following the most recent event. Amending directions on prescriptions to "One each day until November 2006" for example may make it easier to monitor prescribing in ACS patients.